Emerging therapies for COVID-19 pneumonia

Denise Battaglini; Chiara Robba; Lorenzo Ball; Fernanda Ferreira Cruz; Pedro Leme Silva; Paolo Pelosi; Patricia Rieken Macedo Rocco

doi:10.1080/13543784.2020.1771694

Emerging therapies for COVID-19 pneumonia

Expert Opin Investig Drugs. 2020 Jul;29(7):633-637. doi: 10.1080/13543784.2020.1771694. Epub 2020 Jun 1.

Authors

Denise Battaglini^{1

2}, Chiara Robba¹, Lorenzo Ball^{1

3}, Fernanda Ferreira Cruz⁴, Pedro Leme Silva^{4

5}, Paolo Pelosi^{1

3}, Patricia Rieken Macedo Rocco^{4

5}

Affiliations

¹ Anesthesia and Intensive Care, Ospedale Policlinico San Martino, IRCCS for Oncology and Neurosciences , Genoa, Italy.
² Department of Medicine, University of Barcelona (UB) , Barcelona, Spain.
³ Department of Surgical Sciences and Integrated Diagnostic (DISC), University of Genoa , Genoa, Italy.
⁴ Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro , Rio de Janeiro, Brazil.
⁵ National Institute of Science and Technology for Regenerative Medicine , Rio de Janeiro, Brazil.

No abstract available

Keywords: COVID-19; SARS-CoV-2; antiretroviral; antithrombotic; clinical trial; coronavirus; mesenchymal stromal cells; pandemic; respiratory failure.

Publication types

Editorial

MeSH terms

COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy*
Coronavirus Infections / physiopathology
Humans
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / physiopathology
Practice Guidelines as Topic

Grants and funding

This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (421067/2016-0), Fundação Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (E-26/210.910/2016).